Progestal - Altrenogest 0,22%

Description : Progestin Composition : Each 100 ml contains: Altrenogest 0.22 g; Excipients q.s. to 100 ml Action 1- Induction of early ovulation during the estrus season 2- Treatment of lactational anestrus in the absence of the corpus luteum. 3- Suppression of estrus, either during prolonged cycles or in females with regular cycles. 4- Cycle control during the breeding season for efficient use of the stallion or semen. 5- Prevention of early embryonic loss. Indications : PROGESTAL is indicated for suppressing estrus in mares and sows to allow for a more predictable onset of estrus following the completion of treatment. It is used clinically to establish normal cycles during the transitional period in mares, which occurs between anestrus and the breeding season, often in conjunction with an artificial photoperiod. It is most effective for achieving pregnancy when administered during the final phase of the transition period. It is recommended to select mares with significant follicular activity (mares with one or more follicles measuring 20 to 30 millimeters) for treatment during the transition phase. Mares that have been in estrus for 10 days or more and have active ovaries are also considered excellent candidates for progestin treatment. PROGESTAL is effective in mares that are cycling normally to minimize the need for estrus detection, to synchronize estrus, and to facilitate the scheduling of breedings. PROGESTAL is also used to suppress estrus in show mares or racehorses. Although the drug is contraindicated in pregnant mares, its efficacy has been demonstrated in maintaining pregnancy in ovariectomized mares, and it may be beneficial in treating mares that abort as a result of subtherapeutic levels of normal progestins. Contraindications : Do not administer during pregnancy when progesterone levels are normal, or in cases of acute, subacute, or chronic uterine inflammation. Do not administer concurrently with rifampicin. Precautions : Wear gloves when handling the product; Avoid all skin contact. This product should not be handled by: women who suspect they are or are pregnant; Individuals with thrombophlebitis, cerebrovascular or coronary artery disease, breast cancer, estrogen-dependent neoplasms, vaginal bleeding, or liver dysfunction. PACKAGING : Plastic bottles containing 250, 500, and 1000 ml. DOSAGE Mares: Suppression and synchronization of estrus: 0.044 mg/kg (0.02 ml/kg). Maintenance of pregnancy: 22–44 mg/day (10 to 20 ml/day). Estus will occur 2 to 5 days after treatment is completed, and most mares ovulate between 8 and 15 days after treatment ends. Sows: Estrus synchronization: 15–20 mg/animal/day (7 to 9 ml/day). Estrus occurs 4 to 7 days after the last treatment. TREATMENT DURATION Mares: Administer for 15 consecutive days. Sows: Administer for 18 consecutive days. ADMINISTRATION Oral. RESTRICTIONS ON USE Sows must not be slaughtered until 21 days after the last treatment. Do not use in horses intended for human consumption